Abstract
Human plasmacytoid dendritic cells (pDC) are crucial for the modulation of adaptive immune responses in the course of neoplastic, viral and autoimmune diseases. In several of these disorders deregulated pDC-derived interferon-α (IFN-α), a key cytokine produced by pDC, plays a central role. Apart from IFN-α, pDC can produce a variety of other mediators, which are involved in immunological cross-talk. The most recently discovered are the cytotoxic serine protease granzyme B (GrB) and indoleamine 2,3-dioxygenase, which have been described to be involved in the suppression of effector T cell responses. Here we review the regulation of pDC function by a variety of immunomodulatory agents, which may be developed as future candidates for the therapy of a variety of diseases. Moreover, we introduce the novel concept of enhancing immune responses after vaccination in poor responders by increasing pDC-derived IFN-α and simultaneously inhibiting pDC-derived GrB secretion. Finally we discuss potential approaches to abrogate pDC-mediated tolerance induction against tumors and viral infections.
Keywords: pDC, IFN-α, TNF-α, granzyme B, TRAIL, IDO, HMGB1, IL-6, IL-12, IP-10, Interleukin, Vasoactive intestinal peptide
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Volume: 11 Issue: 2
Author(s): Dorit Fabricius and Bernd Jahrsdorfer
Affiliation:
Keywords: pDC, IFN-α, TNF-α, granzyme B, TRAIL, IDO, HMGB1, IL-6, IL-12, IP-10, Interleukin, Vasoactive intestinal peptide
Abstract: Human plasmacytoid dendritic cells (pDC) are crucial for the modulation of adaptive immune responses in the course of neoplastic, viral and autoimmune diseases. In several of these disorders deregulated pDC-derived interferon-α (IFN-α), a key cytokine produced by pDC, plays a central role. Apart from IFN-α, pDC can produce a variety of other mediators, which are involved in immunological cross-talk. The most recently discovered are the cytotoxic serine protease granzyme B (GrB) and indoleamine 2,3-dioxygenase, which have been described to be involved in the suppression of effector T cell responses. Here we review the regulation of pDC function by a variety of immunomodulatory agents, which may be developed as future candidates for the therapy of a variety of diseases. Moreover, we introduce the novel concept of enhancing immune responses after vaccination in poor responders by increasing pDC-derived IFN-α and simultaneously inhibiting pDC-derived GrB secretion. Finally we discuss potential approaches to abrogate pDC-mediated tolerance induction against tumors and viral infections.
Export Options
About this article
Cite this article as:
Fabricius Dorit and Jahrsdorfer Bernd, Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells, Endocrine, Metabolic & Immune Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187153011795564205
DOI https://dx.doi.org/10.2174/187153011795564205 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design NKT Cell-Stimulating Synthetic Glycolipids as Potential Therapeutics for Autoimmune Disease
Current Topics in Medicinal Chemistry Autoimmune Disorders during Pregnancy: Effects of Biomarkers on Maternal Serum Screening and Course of Disease
Current Women`s Health Reviews HMGB-1 as a Target for Inflammation Controlling
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus
Current Pharmaceutical Design CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging
Current Aging Science Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Possible Role of DNA Methylation in the Induction of Systemic Lupus Erythematosus
Current Rheumatology Reviews Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Use of Synbiotics for Ulcerative Colitis Treatment
Current Clinical Pharmacology Molecular Characterization of the T Cell Repertoire Using Immuno-scope Analysis and its Possible Implementation in Clinical Practice
Current Molecular Medicine B-Cell Based Gene Therapy for Inducing Tolerance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry